Rocket Pharmaceuticals Statistics Share Statistics Rocket Pharmaceuticals has 107.9M
shares outstanding. The number of shares has increased by 18.42%
in one year.
Shares Outstanding 107.9M Shares Change (YoY) 18.42% Shares Change (QoQ) 1.04% Owned by Institutions (%) 97.73% Shares Floating 98.88M Failed to Deliver (FTD) Shares 2,015 FTD / Avg. Volume 0.05%
Short Selling Information The latest short interest is 11.73M, so 10.87% of the outstanding
shares have been sold short.
Short Interest 11.73M Short % of Shares Out 10.87% Short % of Float 21.16% Short Ratio (days to cover) 5.33
Valuation Ratios The PE ratio is -4.61 and the forward
PE ratio is -2.67.
Rocket Pharmaceuticals's PEG ratio is
0.71.
PE Ratio -4.61 Forward PE -2.67 PS Ratio 0 Forward PS 9.6 PB Ratio 2.57 P/FCF Ratio -5.53 PEG Ratio 0.71
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Rocket Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 9.3,
with a Debt / Equity ratio of 0.06.
Current Ratio 9.3 Quick Ratio 9.3 Debt / Equity 0.06 Debt / EBITDA -0.1 Debt / FCF -0.12 Interest Coverage -144.86
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-865.37K Employee Count 299 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -82.28% in the
last 52 weeks. The beta is 0.62, so Rocket Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.62 52-Week Price Change -82.28% 50-Day Moving Average 3.09 200-Day Moving Average 7.28 Relative Strength Index (RSI) 51.09 Average Volume (20 Days) 4,360,774
Income Statement
Revenue n/a Gross Profit -9.38M Operating Income -273.2M Net Income -258.75M EBITDA -247.49M EBIT -256.86M Earnings Per Share (EPS) -2.73
Full Income Statement Balance Sheet The company has 163.63M in cash and 25.5M in
debt, giving a net cash position of 138.14M.
Cash & Cash Equivalents 163.63M Total Debt 25.5M Net Cash 138.14M Retained Earnings -1.22B Total Assets 420.98M Working Capital 233.76M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -209.72M
and capital expenditures -5.86M, giving a free cash flow of -215.59M.
Operating Cash Flow -209.72M Capital Expenditures -5.86M Free Cash Flow -215.59M FCF Per Share -2.27
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RCKT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for RCKT is $9,
which is 174.4% higher than the current price. The consensus rating is "Buy".
Price Target $9 Price Target Difference 174.4% Analyst Consensus Buy Analyst Count 13
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 5, 2018. It was a
backward
split with a ratio of 1:4.
Last Split Date Jan 5, 2018 Split Type backward Split Ratio 1:4
Scores Altman Z-Score -2.84 Piotroski F-Score 1
